These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26476230)

  • 81. Treatment advances in psoriatic arthritis.
    Ruderman EM
    Curr Rheumatol Rep; 2005 Aug; 7(4):313-8. PubMed ID: 16045835
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Treating to target in psoriatic arthritis: how to implement in clinical practice.
    Coates LC; Helliwell PS
    Ann Rheum Dis; 2016 Apr; 75(4):640-3. PubMed ID: 26672066
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Tacrolimus: an effective treatment in refractory psoriatic arthritis following biologic failure.
    Lythgoe M; Abraham S
    Clin Exp Rheumatol; 2016; 34(1 Suppl 95):S12-3. PubMed ID: 26211753
    [No Abstract]   [Full Text] [Related]  

  • 84. Current treatment of psoriatic arthritis.
    Mease PJ
    Rheum Dis Clin North Am; 2003 Aug; 29(3):495-511. PubMed ID: 12951864
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Bedside to bench: defining the immunopathogenesis of psoriatic arthritis.
    Bravo A; Kavanaugh A
    Nat Rev Rheumatol; 2019 Nov; 15(11):645-656. PubMed ID: 31485004
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Opportunities and challenges in the treatment of psoriatic arthritis.
    FitzGerald O; Ritchlin C
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):440-452. PubMed ID: 31171314
    [TBL] [Abstract][Full Text] [Related]  

  • 87. PORTUGUESE RECOMMENDATIONS FOR THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS--2015 UPDATE.
    Vieira-Sousa E; Machado PM; Costa J; Ribeiro A; Aguiar R; Cerqueira M; Neto A; Bernardo A; Cordeiro A; Duarte C; Vinagre F; Canhão H; Santos H; Neves JS; Cunha-Miranda L; Silva M; Santos MJ; Bernardes M; Bogas M; Abreu P; Viana-Queiroz M; Barros R; Falcão S; Pimenta S; Teixeira V; Fonseca JE; Barcelos A;
    Acta Reumatol Port; 2015; 40(3):275-90. PubMed ID: 26610694
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy.
    Elliott A; McGonagle D; Rooney M
    Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi38-vi52. PubMed ID: 34951926
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Tight control of inflammatory activity in the treatment of early psoriatic arthritis : A reasonable therapy strategy for improvement of patient care?].
    Köhm M
    Z Rheumatol; 2016 Dec; 75(10):1032-1034. PubMed ID: 27844154
    [No Abstract]   [Full Text] [Related]  

  • 90. Interleukin-17 inhibition in psoriatic arthritis.
    Boyd T; Kavanaugh A
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S119-23. PubMed ID: 26471234
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Racial disparities in comorbidities of patients with psoriatic arthritis.
    Ross Y; Jaleel S; Magrey M
    Rheumatol Int; 2023 Aug; 43(8):1525-1529. PubMed ID: 37017711
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Recent Advances in Psoriatic Arthritis from Obscurity to Prominence.
    Parikh T; Joshi VR
    J Assoc Physicians India; 2015 Oct; 63(10):42-6. PubMed ID: 27608691
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pregnancy Outcomes in Patients with Psoriatic Arthritis.
    Mouyis MA; Thornton CC; Williams D; Giles IP
    J Rheumatol; 2017 Jan; 44(1):128-129. PubMed ID: 28042130
    [No Abstract]   [Full Text] [Related]  

  • 94. Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: A review of literature.
    Pouw J; Leijten E; Radstake T; Boes M
    Clin Immunol; 2020 Feb; 211():108318. PubMed ID: 31783160
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [The therapeutic status of biological and targeted synthetic disease-modifying antirheumatic drugs in the management of psoriatic arthritis].
    Cheng G; Su Y
    Zhonghua Nei Ke Za Zhi; 2021 May; 60(5):487-491. PubMed ID: 33906282
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Current treatment strategies and recommendations in psoriatic arthritis.
    Kao PE; Lee YH; Ma KS; Ker A; Leung YY
    Int J Rheum Dis; 2023 Jan; 26(1):8-10. PubMed ID: 36591904
    [No Abstract]   [Full Text] [Related]  

  • 97. The use of biomarkers as a tool for novel psoriatic disease drug discovery.
    Aggarwal D; Arumalla N; Jethwa H; Abraham S
    Expert Opin Drug Discov; 2018 Sep; 13(9):875-887. PubMed ID: 30124339
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Treatment Continuation Guidance in Psoriatic Arthritis Clinical Care.
    Orbai AM
    J Rheumatol; 2020 Nov; 47(11):1600-1602. PubMed ID: 33139521
    [No Abstract]   [Full Text] [Related]  

  • 99. Making the next steps in psoriatic arthritis management: current status and future directions.
    Sritheran D; Leung YY
    Ther Adv Musculoskelet Dis; 2015 Oct; 7(5):173-86. PubMed ID: 26425146
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Treat to target in PsA should focus on clinical measures. Response to: 'DAPSA versus cDAPSA: do we need to use CRP?' by Gonçalves
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2020 Nov; 79(11):e143. PubMed ID: 31331923
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.